|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GROWTH, DIFFERENTIATION, AND APOPTOSIS
1The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka; 2Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto; 3Department of Anesthesia, Kyoto University Hospital, Kyoto; 4Department of Anesthesiology, Kansai Medical University, Osaka; 5Department of Hematology and Oncology, Kyoto University Hospital, Kyoto University, Kyoto, Japan; and 6Vascular Biology Program, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland
Submitted 12 December 2005 ; accepted in final form 7 February 2006
| ABSTRACT |
|---|
|
|
|---|
and HIF-1
as well as increased HIF-1 transcriptional activity leading to increased expression of HIF-1 target genes. The increased HIF-1 activity in differentiated THP-1 cells resulted from the combined effect of increased HIF-1
mRNA levels and increased HIF-1
protein synthesis. Differentiation-induced HIF-1
protein and mRNA and HIF-1-dependent gene expression was blocked by treating cells with an inhibitor of the protein kinase C or MAP kinase signaling pathway. THP-1 cell differentiation was also associated with increased phosphorylation of the translational regulatory proteins p70 S6 kinase, S6 ribosomal protein, eukaryotic initiation factor 4E, and 4E binding protein 1, thus providing a possible mechanism for the modulation of HIF-1
protein synthesis. RNA interference studies demonstrated that HIF-1
is dispensable for macrophage differentiation but is required for functional maturation. translation; RNA interference
In response to hypoxia, dramatic changes in gene expression occur, leading to increased synthesis of proteins, such as erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor (VEGF), and matrix metalloproteinases, which mediate cellular and tissue adaptation (16). The changes in gene expression are controlled by the transcriptional activator hypoxia-inducible factor 1 (HIF-1) (46). HIF-1 is a heterodimer composed of a constitutively expressed HIF-1
subunit and an inducibly expressed HIF-1
subunit (55). The regulation of HIF-1 activity occurs at multiple levels in vivo. Among these, the mechanisms regulating HIF-1
protein expression and transcriptional activity have been most extensively analyzed. O2-dependent hydroxylation of proline residues 402 and 564 in HIF-1
is required for binding of the von Hippel-Lindau tumor-suppressor protein (VHL), which is the recognition component of a ubiquitin-protein ligase that targets HIF-1
for rapid proteasomal degradation in nonhypoxic cells (19, 20). Under hypoxic conditions, hydroxylation of HIF-1
is inhibited due to substrate (O2) limitation, resulting in HIF-1
protein stabilization (8, 19, 20). Transcriptional activity of HIF-1
is also O2 regulated (22, 39). Asparagine residue 803 of HIF-1
is hydroxylated by factor-inhibiting HIF-1 under normoxic conditions, and the hydroxylated form of HIF-1
cannot bind to the coactivators p300 and CREB-binding protein (CBP) (2, 30, 34). The iron chelator desferrioxamine (DFX) induces HIF-1
stabilization and transactivation under normoxic conditions (22), presumably by inhibiting the prolyl and asparaginyl hydroxylases, which contain Fe2+ at their catalytic sites (43). In contrast, HIF-1
is constitutively expressed in most cell types (18, 57).
Several reports (5, 48) have described expression of HIF-1
and VEGF in macrophages. Conditional gene targeting in the myeloid cell lineage has demonstrated that HIF-1
plays essential roles in antibacterial (38) and inflammatory (7) responses. The proinflammatory effect was attributed primarily to regulation of glycolytic metabolism by HIF-1, suggesting a housekeeping role rather than participation in a dynamic response. Proinflammatory cytokines and other stimuli, including TNF-
, IL-1, and LPS, activate HIF-1 (4, 12, 23). However, to the best of our knowledge, changes in HIF-1 activity associated with monocytic differentiation have not been previously reported. In this study, we used the human monocytic leukemia cell line THP-1 (52), which is a multifaceted model for the study of monocyte/macrophage differentiation (3), and primary monocyte-derived macrophages from healthy volunteers. We demonstrate that HIF-1 is activated during the macrophage-like differentiation of the monocytic THP-1 cell line that is induced by exposure to phorbol-12-myristate 13-acetate (PMA), all-trans-retinoic acid (ATRA), or 1
,25-dihydroxy vitamin D3 (VitD) and primary monocyte-derived macrophages. We also demonstrate that not only HIF-1
but also HIF-1
protein expression is induced during the differentiation process. Finally, we show that in addition to activating HIF-1 under nonhypoxic conditions, differentiated THP-1 cells manifest an augmented induction of HIF-1 activity in response to hypoxia.
| EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Preparation of macrophages from human peripheral blood. Human peripheral blood monocyte-derived macrophages were prepared as previously described (37). Briefly, mononuclear cells were isolated from heparinized peripheral blood from healthy volunteers by Percoll-gradient centrifuge. All subjects gave written informed consent before enrolling in the study. The monocytes were placed onto plates and were washed twice to eliminate nonadherent cells after 2 h. Complete medium was added to the plates, and the cells were incubated. On day 5 of culture, >98% of adherent cells were macrophages, as determined by staining of nonspecific esterase and fluorescence analysis cell sorting.
Plasmid constructs.
Reporter plasmid p2.1 contains a 68-bp hypoxia response element (HRE) from the enolase 1 gene, a simian virus-40 (SV40) promoter, and firefly luciferase coding sequences (47). Plasmid pVEGF-KpnI contains nucleotides 2274 to +379 of the VEGF gene inserted into luciferase reporter pGL2-Basic (Promega) (9). The Renilla luciferase expression plasmid pRL-SV40 was from Promega (Madison, WI). pCMV-3xFLAG-HIF-1
DN, which encodes a FLAG-tagged dominant negative form of HIF-1
, was generated by subcloning from pCEP4-HIF-1
·NB·AB (21, 22).
Hypoxic treatment. Tissue culture dishes were transferred to a modular incubator chamber (Billups-Rothenberg, Del Mar, CA), which was flushed with a 1% O2-5% CO2-94% N2 gas mixture, sealed, and stored at 37°C (13, 24).
Immunoblot assays.
Whole cell lysates were prepared by incubating cells for 30 min in cold RIPA buffer containing 2 mM dithiothreitol, 1 mM NaVO3, and Complete protease inhibitor (Roche Applied Science, Tokyo, Japan) (13, 14). Samples were centrifuged at 10,000 g to pellet cell debris. For HIF-1
, HIF-1
, and
-actin, 100-µg aliquots of lysates were fractionated by 7.5% SDS-PAGE and subjected to immunoblot assay using mouse monoclonal antibodies against HIF-1
and HIF-1
(H1
67 and H1
234; Novus Biologicals, Littleton, CO) or
-actin (Sigma) at 1:1,000 dilution. The signal was developed using ECL reagent (Amersham Biosciences, Piscataway, NJ). For detection of phosphorylated proteins, THP-1 cells were treated with PMA or vehicle and 50-µg aliquots of cell lysate were analyzed using specific antibodies against: phosphorylated p44/42MAPK (Thr-202/Tyr-204), phosphorylated Akt (Ser-473), phosphorylated ribosomal protein S6 (Ser-235/236), phosphorylated p70 S6 kinase (p70S6K) (Thr-389), phosphorylated 4E-BP1 (Ser-65), or phosphorylated elF-4E (Ser-209) (1:1,000 dilution) (Cell Signaling Technology, Beverly, MA) (10, 24).
RT-PCR.
The RT-PCR protocol was described previously (1, 50, 51). After treatment, cells were harvested and RNA was isolated with TRIzol (Invitrogen). One microgram of total RNA was subjected to first-strand cDNA synthesis using random hexamers (SuperScript II RT kit, Invitrogen) (1, 50, 51). cDNAs were amplified with TaqGold polymerase (Roche, Mannheim, Germany) in a thermal cycler with specific primers. A primer pair for detection of the truncated form of HIF-1
lacking exon 11 is described elsewhere (6). For each primer pair, PCR was optimized for cycle number to obtain linearity between the amount of input RT product and output PCR product. Thermocycling conditions were 30 s at 94°C, 60 s at 57°C, and 30 s at 72°C for 30 (CD14, CD36), 28 [glucose transporter 1 (GLUT1)], 25 [carboxypeptidase M, VEGF, lactate dehydrogenase A (LDHA), HIF-1
, and HIF-1
] cycles preceded by 10 min at 94°C. PCR products were fractionated by 1% SeaKem GTG Agarose gel electrophoresis, stained with ethidium bromide, and visualized with UV light.
Reporter gene assays. Reporter assays were performed in THP-1 cells as described previously (13, 14). In each transfection, test plasmid, reporter gene plasmid p2.1, and the control plasmid pRL-SV40, containing a SV40 promoter upstream of Renilla reniformis (sea pansy) luciferase coding sequences (Promega), containing a thymidine kinase promoter upstream of R. reniformis luciferase coding sequences, were premixed with Lipofectamine 2000 transfection reagent (Invitrogen). After treatment, the cells were harvested and the luciferase activity was determined using the Dual-Luciferase Reporter Assay System (Promega). The ratio of firefly to Renilla luciferase activity was determined. For each experiment, at least two independent transfections were performed in triplicate. Normalized means ± SD of three independent transfections is shown as relative activity (13).
In vitro HIF-1
-VHL interaction assay.
Plasmids used in assays were described previously (34). Glutathione S-transferase-HIF-1
(429608) fusion protein was expressed in Escherichia coli (34). Biotinylated methionine-labeled proteins were generated in reticulocyte lysates with the TNT T7-coupled transcription/translation system using Transcend Biotinylated tRNA (Promega). Aliquots (25 µg) of THP-1 cell lysate were preincubated with or without DFX for 30 min at 30°C. A 5-µl aliquot of in vitro-translated biotinylated VHL protein was mixed with 4 µg of glutathione S-transferase fusion protein in a final volume of 200 µl of binding buffer (Dulbeccos PBS, pH 7.4, and 0.1% Tween 20) and incubated for 2 h at 4°C with rotation, followed by addition of 10 µl of glutathione-Sepharose 4B beads (Pharmacia) and incubation at 4°C for 1 h. The beads were pelleted, washed three times in binding buffer, pelleted, resuspended in Laemmli sample buffer, and analyzed with SDS-PAGE. Proteins were transferred to PVDF membrane and visualized using streptavidin-labeled horseradish peroxidase and ECL reagent (Amersham Biosciences).
RNA interference.
To generate siRNAHIF-1
, two oligonucleotides consisting of ribonucleosides, except for the presence of 2'-deoxyribonucleosides (dTdT) at the 3' end, 5'-AGAGGUGGAUAUGUGUGGGdTdT-3' and 5'-CCCACACAUAUCCACCUCUdTdT-3', were synthesized and annealed (Dharmacon Research, Lafayette, CO) (29). siRNAHIF-1
was introduced into THP-1 cells by electroporation using the Nucleofector (Amaxa Biosystems) following a protocol provided by the manufacturer.
Measurement of lactate. Conditioned medium from triplicate macrophage cell cultures was harvested and assayed for lactate content by colorimetric detection (Sigma), according to the manufacturers instructions. Sample values were calculated from a lactate standard curve and normalized to cell lysate protein content.
| RESULTS |
|---|
|
|
|---|
|
protein expression (Fig. 1C, top) was undetectable in undifferentiated THP-1 cells (lane 1) but was induced in differentiated THP-1 cells (lane 2). Hypoxia induced HIF-1
expression in undifferentiated THP-1 cells (lane 3). Remarkably, the combination of differentiation and hypoxia had a synergistic effect on HIF-1
expression (lane 4). On the other hand, HIF-2
expression was not induced significantly by differentiation. HIF-1
protein expression (Fig. 1C, middle) was observed in THP-1 cells under nonhypoxic conditions and was not induced by hypoxia (compare lanes 1 and 3). However, HIF-1
expression was induced in response to differentiation (lanes 2 and 4). Expression of
-actin protein (Fig. 1C, bottom) was not affected by hypoxia or differentiation.
To determine whether the induction of HIF-1
and HIF-1
expression was specific to PMA-elicited signaling or common to differentiation induced by other agents, we examined the effect of two other inducers of monocytic differentiation, VitD and ATRA (15, 58). VitD (100 µM) induced both HIF-1
and HIF-1
protein expression under nonhypoxic conditions (Fig. 1D, lane 2). Exposure of THP-1 cells to 1 µM ATRA also induced both HIF-1
and HIF-1
protein expression at 20% O2 conditions (lane 3). Finally, we examined the induction of HIF-1 proteins using monocytes from human peripheral blood. Monocytes isolated from peripheral blood were allowed to differentiate to macrophages. The cells were harvested and subjected to Western blot analysis (Fig. 1E). HIF-1
and HIF-1
protein expression was induced in response to the differentiation of peripheral blood monocytes into macrophages, similar to THP-1 cells. In contrast, HIF-2
expression was constant during differentiation.
Next, we investigated the dose dependency and time course of HIF-1 protein expression during the differentiation process induced by PMA or ATRA. PMA induced HIF-1
protein accumulation in a dose-dependent manner with a peak response at 100 nM (Fig. 2A). Exposure of cells to 100 nM PMA resulted in a time-dependent induction of HIF-1
that peaked at 46 h and decreased gradually but did not return to the basal level (Fig. 2B) even 7 days after PMA exposure (data not shown). Notably, after 48 h, a form of HIF-1
protein with reduced electrophoretic mobility predominated (lanes 9 and 10). In contrast, HIF-1
expression did not significantly change until 12 h (Fig. 2B) and then increased gradually over 7 days (data not shown). Expression of
-actin was constant. A similar pattern of HIF-1 protein expression was observed in cells exposed to ATRA (Fig. 2C).
|
but not that of HIF-1
(Fig. 2D). The induction of HIF-1
was weak and transient and decreased to the basal level after 12 h, suggesting that the acute effect of PMA-induced signaling on HIF-1 is different from the effect of PMA as a differentiation factor. Differentiation of THP-1 cells induces HIF-1-mediated transcriptional activation. We investigated by RT-PCR whetherdifferentiation induced gene expression downstream of HIF-1. VEGF, GLUT1, and LDHA mRNA expression was induced under nonhypoxic conditions in cells exposed to PMA (Fig. 3A, lane 2) or hypoxic conditions (lane 3). Consistent with the effect on HIF-1 protein levels, differentiation and hypoxia synergistically induced GLUT1 and VEGF mRNA expression (lane 4). Macrophages typically produce most of their ATP through glycolysis (33), and HIF-1 is a key regulator of glycolysis (44, 45, 47). We performed an experiment to determine the role of HIF-1 in THP-1 cells after macrophage differentiation. As shown in Fig. 3B, lactate levels in culture media increased with differentiation and this was suppressed by treatment with 25 µM ascorbate, a potent HIF-1 inhibitor (27). Lipopolysaccharide induced accumulation of lactate, and the accumulation is also suppressed by ascorbate.
|
Differentiation does not prolong HIF-1
or HIF-1
protein half-life and does not inhibit interaction between HIF-1
and VHL.
To determine whether the differentiation process affected HIF-1
protein half-life (13, 24), THP-1 cells were treated with PMA for 48 h or with DFX for 4 h to induce HIF-1
expression, and then CHX was added to block ongoing protein synthesis. In the presence of CHX, the half-life of HIF-1
was >30 min in DFX-treated cells, due to inhibition of prolyl hydroxylation, but <15 min in PMA-differentiated cells (Fig. 4A). Neither DFX nor differentiation affected the half-life of HIF-1
protein.
|
is required for binding of VHL, the recognition component of a ubiquitin-protein ligase that targets HIF-1
for rapid proteasomal degradation in nonhypoxic cells. To study whether differentiation affected HIF-1
hydroxylase activity, the binding between HIF-1
and VHL was investigated. As shown in Fig. 4B, lysate from undifferentiated THP-1 cells promoted the binding. Lysates from PMA- and ATRA-differentiated THP-1 cells also promoted HIF-1
-VHL interaction.
As shown in Fig. 4, A and B, induction of HIF-1
and HIF-1
protein expression is not due to protein stabilization. Therefore, we evaluated whether differentiation could modify the levels of HIF-1 mRNAs. As seen in Fig. 4C, differentiation increased HIF-1
but not HIF-1
mRNA levels in THP-1 cells and in macrophages from peripheral blood. These experiments suggest that differentiation-stimulated HIF-1
protein expression is due at least in part to increased HIF-1
mRNA levels.
HIF-1
is not required for THP-1 cells to undergo macrophage differentiation.
To further investigate whether HIF-1 is required for the macrophage differentiation of THP-1 cells in response to PMA, THP-1 cells were mock transfected or transfected with a small interfering RNA (siRNAHIF-1) that targets HIF-1
mRNA for degradation. siRNA targeted to GFP mRNA was also introduced into THP-1 cells as a negative control. Cells were treated with PMA or ATRA (data not shown) for 48 h and were then harvested for immunoblot assay with anti-HIF-1
Ab or RT-PCR with oligonucleotide pairs for CD36, a marker of macrophage differentiation. Introduction of siRNAHIF-1
effectively silenced the expression of HIF-1
protein even under hypoxic conditions (Fig. 5A). However, PMA induced macrophage differentiation of siRNAHIF-1
-transfected THP-1 cells as well as siRNAGFP-transfected cells (Fig. 5B). Moreover, compared with siRNAGFP, siRNAHIF-1
did not alter expression of CD36 (Fig. 5C).
|
mRNA alternative splicing.
We investigated whether macrophage differentiation induced by PMA was associated with the expression of an alternatively spliced form of HIF-1
mRNA lacking exon 11, as previously reported (6). With the use of a primer pair spanning exon 14 (Fig. 5D, lanes 1 and 2) or exon 11 (lanes 3 and 4), we did not detect any change in the size of the RT-PCR product obtained by amplification of mRNA isolated from cells before and after differentiation. Thus PMA-induced differentiation of THP-1 cells did not have any detectable qualitative effect on HIF-1
mRNA expression. Impact of kinase inhibitors on HIF-1 activation. To examine the signaling pathways leading to the induction of HIF-1 protein expression in differentiated THP-1 cells, we focused on various kinases, including phosphatidylinositol 3-kinase (PI3-kinase), tyrosine kinases, mitogen-activated protein kinase (MAPK), and mammalian target of rapamycin (mTOR). We performed assays under two different protocols. One examined the short-term (6 h) effect of PMA on THP-1 cells and the other investigated the long-term (48 h) effect on THP-1 cells that had differentiated in response to PMA treatment.
THP-1 cells were pretreated with LY-294002, wortmannin, genistein, PD-98059, rapamycin, or GF109203X, which are selective pharmacological inhibitors of PI3-kinase, tyrosine kinases, MEK, mTOR, and protein kinase C (PKC), respectively, for 30 min, treated with 100 nM PMA for 6 h, and then harvested for immunoblot assay (Fig. 6A). PMA treatment increased HIF-1
protein expression (Fig. 6A, top, lane 2). All of the agents (lanes 4-8) except genistein (lane 3) inhibited the induction of HIF-1
protein expression in THP-1 cells. HIF-1
protein expression was not induced and not affected by any of the kinase inhibitors (Fig. 6A, middle).
-Actin expression was also constant (bottom).
|
protein (Fig. 6B, top). In contrast to the 6-h protocol, HIF-1
expression was induced after the 48-h incubation with PMA, an effect that was not blocked by treatment with kinase inhibitors (Fig. 6B, middle).
-Actin expression was constant (Fig. 6B, bottom). These results are consistent with data presented in Fig. 2, which indicated that the short-term effect of PMA on HIF-1 differs mechanistically from the long-term effect of PMA as a differentiation factor. Next, the effects of the kinase inhibitors on HIF-1 mRNAs were investigated. As shown in Fig. 6C, HIF-1
mRNA induction in response to PMA-induced differentiation was suppressed by the PKC inhibitor GF109203X. In contrast, HIF-1
mRNA expression was not affected by any of the kinase inhibitors. Differentiation-induced activation of MAPK, PI3-kinase, and translational regulatory proteins. HIF-1 activity induced by the stimulation of receptor tyrosine kinases or G protein-coupled receptors requires MAPK and/or PI3-kinase signaling (10, 11, 13, 31). To determine whether the MAPK- and PI3K-mediated pathways were activated in PMA-treated THP-1 cells, the phosphorylation of p42ERK2/p44ERK1 and AKT were analyzed in THP-1 cells and peripheral blood monocyte-derived macrophages (Fig. 7). Phosphorylation of p42ERK2/p44ERK1 was induced by PMA treatment in THP-1 cells in a time-dependent manner. The phosphorylation peaked at 15 min after PMA stimulation and declined thereafter (Fig. 7A). However, increased levels of ERK phosphorylation were sustained for at least 72 h (Fig. 7B). In contrast, AKT phosphorylation (Ser-473) was not prominent until 6 h, and then gradually increased (Fig. 7A). The phosphorylation peaked at 48 h and remained elevated at 72 h (Fig. 7B). The total protein levels of ERK and AKT were constant during the process (Fig. 7, A and B). As in THP-1 cells, phosphorylation of Erk and Akt was induced after differentiation of monocyte-derived macrophages (Fig. 3C).
|
| DISCUSSION |
|---|
|
|
|---|
and HIF-1
protein levels increase and cells acquire the ability to respond to hypoxia more robustly. Interestingly, HIF-2
expression is not altered by differentiation, suggesting an exclusive role of HIF-1
:HIF-1
heterodimers in activated macrophages. Thus HIF-1 activity in monocytes/macrophages is modulated by both O2-dependent and O2-independent signals. Since the discovery of THP-1 cells in 1980 by Tsuchiya et al. (53), THP-1 cells have been used for study of monocyte-macrophage differentiation (3, 52). After treatment with phorbol esters, VitD, or ATRA, THP-1 cells differentiate into macrophage-like cells, which mimic native monocyte-derived macrophages in several respects. After differentiation, THP-1 cells acquire phagocytic activity and expression of scavenger receptors are observed (28, 41). Compared with other human myeloid cell lines, such as HL-60, U937, KG-1, or HEL cell lines, differentiated THP-1 cells behave more like native monocyte-derived macrophages. Because of these characteristics, the THP-1 cell line provides a valuable model for studying the mechanisms involved in macrophage differentiation, and for exploring the regulation of macrophage-specific genes as they relate to physiological functions displayed by these cells. In this study, human monocytic THP-1 cells were differentiated into adherent macrophages by treatment with PMA, ATRA, or VitD, as evidenced by the induction of macrophage differentiation markers such as CD14, CD36, and carboxypeptidase M.
Although the precise molecular mechanisms by which PMA, ATRA, or VitD induces THP-1 cells to differentiate into macrophages have not been delineated, the primary cellular targets of these agents are different. Yet they each induced the accumulation of HIF-1
and HIF-1
protein, and expression of the HIF-1-regulated VEGF gene. Differentiation induced by each of these agents was associated with increased levels of HIF-1
, which peaked at 6 h and then gradually decreased but did not return to basal levels. Thus, ATRA, PMA, and VitD each induce both macrophage differentiation and a sustained increase in the expression of HIF-1
and HIF-1
protein. The effect of PMA on Jurkat T cells was different from its effect on THP-1 cells with respect to HIF-1 protein accumulation. PMA treatment induced HIF-1
accumulation only transiently and did not induce HIF-1
expression in Jurkat T cells. In contrast, PMA induced the differentiation of THP-1 cells and sustained accumulation of both HIF-1
and HIF-1
protein. Recently, Chun et al. (6) reported that PMA treatment of Hep3B and human embryonic kidney-293 cells induced the expression of a HIF-1
mRNA splice variant lacking exon 11, which encodes an isoform of HIF-1
that is stable under nonhypoxic conditions. However, the results presented in Fig. 5D demonstrate that this does not occur during the differentiation of THP-1 cells, providing further evidence that differentiation-induced HIF-1 activation is different from activation induced by acute PMA exposure.
Another important and novel finding of this study is the induction of HIF-1
protein without any increase in the cognate mRNA levels during differentiation of THP-1 cells treated with PMA, ATRA, or VitD. HIF-1
induction was not observed in THP-1 cells after hypoxia treatment, indicating that the induction was specifically associated with differentiation. This co-induction of both subunits of HIF-1 during the differentiation process confers robust and sustained activation of HIF-1 in macrophages. The kinetics of induction were different for HIF-1
and HIF-1
. Kinase inhibitors also had different effects on the expression of HIF-1
and HIF-1
, suggesting that discrete molecular mechanisms underlie the induction of each subunit.
Different molecular mechanisms also control differentiation- and hypoxia-induced HIF-1
expression. Unlike hypoxia, differentiation did not increase the half-life of HIF-1
protein in THP-1 cells. Moreover, because the levels of mRNAs encoding the HIF-1
hydroxylases PHD-2, PHD-3, and the factor inhibiting HIF-1 increased during the differentiation process (T. Oda and K. Hirota, unpublished data), reduced expression of these enzymes is unlikely to be the cause of increased HIF-1
accumulation and HIF-1 activity. The induction of HIF-1
protein during differentiation is largely dependent on activation of the PKC and MAPK pathways. Kinase inhibitors suppress PMA-induced HIF-1 activation in a time-dependent manner. All of the kinase inhibitors other than genistein acutely blocked acute PMA-induced HIF-1
protein accumulation. In contrast, HIF-1
protein expression after 48-h treatment, i.e., after differentiation, was only sensitive to the MEK-ERK inhibitor PD-98059 and the PKC inhibitor GF109203X. The MEK-ERK pathway stimulates the phosphorylation of eIF-4E, which is required for its mRNA cap binding activity. ERK has also been shown to phosphorylate 4E-BP1, which blocks its ability to inhibit eIF-4E. Thus macrophage differentiation both de-represses (via phosphorylation of 4E-BP1) and activates (via phosphorylation of eIF-4E and p70S6K) protein synthesis. On the other hand, HIF-1
mRNA induction is sensitive to only GF109203X. Thus, HIF-1
protein induction is dependent on both increased mRNA levels and an increased rate of protein translation from mRNA, which are regulated by different mechanisms.
Combined with its well-established roles in regulating angiogenesis and metabolic adaptation, these results add yet another dimension to the multifaceted involvement of HIF-1 in macrophage activity. Macrophages must produce sufficient ATP via glycolysis to generate an O2 burst under hypoxic conditions (25, 44). In mice with myeloid-specific deficiency of HIF-1
, monocytes differentiate into macrophages but the metabolic defect results in profound impairment of myeloid cell aggregation, motility, invasiveness, and bacterial killing (7). The dramatic effect of HIF-1
loss of function is consistent with our demonstration that HIF-1
, but not HIF-2
, is induced during monocyte-to-macrophage differentiation. We also show that differentiation induced the expression of mRNAs encoding GLUT1 and LDHA, which are required for intracellular glucose transport and the conversion of pyruvate to lactate, respectively, the first and last steps of glycolysis. Further studies are in progress to delineate the role of HIF-1 in macrophage function and to determine whether HIF-1 inhibitors may be useful as anti-inflammatory agents. In summary, our results suggest that increased expression of HIF-1
and HIF-1
promotes the adaptation of macrophages to the low levels of O2 and glucose that are commonly observed at sites of inflammation.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
2. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, and Livingston DM. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93: 1296912973, 1996.
3. Auwerx J. The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia 47, 1991.
4. Blouin C, Page E, Soucy G, and Richard D. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1
. Blood 103: 11241130, 2004.
5. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, and Lewis CE. Expression of HIF-1 by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 196: 204212, 2002.[CrossRef][Web of Science][Medline]
6. Chun Y, Lee K, Choi E, Bae S, Yeo E, Huang L, Kim M, and Park J. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1
isoform: implications for tumor promotion. Cancer Res 63: 87008707, 2003.
7. Cramer T, Yamanishi Y, Clausen B, Forster I, Pawlinski R, Mackman N, Haase V, Jaenisch R, Corr M, Nizet V, Firestein G, Gerber H, Ferrara N, and Johnson R. HIF-1
is essential for myeloid cell-mediated inflammation. Cell 112: 645657, 2003.[CrossRef][Web of Science][Medline]
8. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, ORourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 4354, 2001.[CrossRef][Web of Science][Medline]
9. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koons RD, and Semenza GL. Activation of vascular endothetial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 46044613, 1996.[Abstract]
10. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, and Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 3820538211, 2002.
11. Fukuda R, Kelly B, and Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 63: 23302334, 2003.
12. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, and Jelkmann W. Interleukin-1
and tumor necrosis factor-
stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 15611567, 1999.
13. Hirota K, Fukuda R, Takabuchi S, Kizaka-Kondoh S, Adachi T, Fukuda K, and Semenza GL. Induction of hypoxia-inducible factor 1 activity by muscarinic acetylcholine receptor signaling. J Biol Chem 279: 4152141528, 2004.
14. Hirota K and Semenza GL. Small GTPase protein Rac1 plays an essential role in hypoxia-inducible factor 1 activation in hypoxia. J Biol Chem 276: 2116621172, 2001.
15. Hmama Z, Nandan D, Sly L, Knutson KL, Herrera-Velit P, and Reiner NE. 1
,25-Dihydroxyvitamin D3-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. J Exp Med 190: 15831594, 1999.
16. Hochachka PW, Buck LT, Doll CJ, and Land SC. Unifying theory of hypoxia tolerance: molecular/metabolic defence and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 93: 94939498, 1996.
17. Hoebe K, Janssen E, and Beutler B. The interface between innate and adaptive immunity. Nat Immun 5: 971974, 2004.
18. Huang LE, Arany Z, Livingston DM, and Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its
-subunit. J Biol Chem 271: 3225332259, 1996.
19. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG Jr. HIF
targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464468, 2001.
20. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ. Targeting of HIF-
to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468472, 2001.
21. Jiang BH, Rue E, Wang GL, Roe R, and Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271: 1777117778, 1996.
22. Jiang BH, Zheng JZ, Leung SW, Roe R, and Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1
. Modulation of transcriptional activity by oxygen tension. J Biol Chem 272: 1925319260, 1997.
23. Jung Y, Isaacs J, Lee S, Trepel J, and Neckers L. IL-1
-mediated up-regulation of HIF-1
via an NF
B/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 14: 21152117, 2003.
24. Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T, Semenza GL, and Hirota K. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling. J Biol Chem 279: 25502558, 2004.
25. Kawaguchi T, Veech RL, and Uyeda K. Regulation of energy metabolism in macrophages during hypoxia. Roles of fructose 2,6-bisphosphate and ribose 1,5-bisphosphate. J Biol Chem 276: 2855428561, 2001.
26. Kempner W. The nature of leukemic blood cells as determined by their metabolism. J Clin Invest 18: 291300, 1939.[Web of Science][Medline]
27. Knowles H, Raval R, Harris A, and Ratcliffe P. Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 63: 17641768, 2003.
28. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, and Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 343: 531535, 1990.[CrossRef][Medline]
29. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, and Semenza GL. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 11381143, 2003.
30. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, and Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16: 14661471, 2002.
31. Laughner E, Taghavi P, Chiles K, Mahon PC, and Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1
(HIF-1
) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 39954004, 2001.
32. Lewis C and Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 167: 627635, 2005.
33. Lewis JS, Lee JA, Underwood JC, Harris AL, and Lewis CE. Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol 66: 889900, 1999.[Abstract]
34. Mahon PC, Hirota K, and Semenza GL. FIH-1: a novel protein that interacts with HIF-1
and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev 15: 26752685, 2001.
35. Medzhitov R and Janeway C Jr. Innate immunity. N Engl J Med 343: 338344, 2000.
36. Murdoch C, Muthana M, and Lewis C. Hypoxia regulates macrophage functions in inflammation. J Immunol 175: 62576263, 2005.
37. Nakabo Y, Harakawa N, Yamamoto K, Okuma M, Uno K, and Sasada M. Mechanism of leukemic cell lysis by activated human macrophages: leukemic cells can be lysed without direct contact. Int J Hematol 60: 5157, 1994.[Web of Science][Medline]
38. Peyssonnaux C, Datta V, Cramer T, Doedens A, Theodorakis E, Gallo R, Hurtado-Ziola N, Nizet V, and Johnson R. HIF-1
expression regulates the bactericidal capacity of phagocytes. J Clin Invest 115: 18061815, 2005.[CrossRef][Web of Science][Medline]
39. Pugh CW, ORourke JF, Nagao M, Gleadle JM, and Ratcliffe PJ. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem 272: 1120511214, 1997.
40. Reiss M and Roos D. Differences in oxygen metabolism of phagocytosing monocytes and neutrophils. J Clin Invest 61: 480488, 1978.[Web of Science][Medline]
41. Rohrer L, Freeman M, Kodama T, Penman M, and Krieger M. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. Nature 343: 570572, 1990.[CrossRef][Medline]
42. Sawyer RG, Spengler MD, Adams RB, and Pruett TL. The peritoneal environment during infection. The effect of monomicrobial and polymicrobial bacteria on PO2 and pH. Ann Surg 213: 253260, 1991.[Web of Science][Medline]
43. Schofield CJ and Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol 9: 722731, 1999.[CrossRef][Web of Science][Medline]
44. Seagroves TN, Ryan HE, Lu H, Wouters BG, Knapp M, Thibault P, Laderoute K, and Johnson RS. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 21: 34363444, 2001.
45. Semenza GL. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med 131: 207214, 1998.[CrossRef][Web of Science][Medline]
46. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551578, 1999.[CrossRef][Web of Science][Medline]
47. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, and Giallongo A. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 271: 3252932537, 1996.
48. Shatrov VA, Sumbayev VV, Zhou J, and Brüne B. Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1
(HIF-1
) accumulation via redox-dependent mechanisms. Blood 101: 48474849, 2003.
49. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita T, and Yonehara S. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 275: 4066340666, 2000.
50. Takabuchi S, Hirota K, Nishi K, Oda S, Oda T, Shingu T, Takabayashi A, Adachi T, Semenza GL, and Fukuda K. The inhibitory effect of sodium nitroprusside on HIF-1 activation is not dependent on nitric oxide-soluble guanylyl cyclase pathway. Biochem Biophys Res Commun 324: 417423, 2004.[CrossRef][Web of Science][Medline]
51. Takabuchi S, Hirota K, Nishi K, Oda S, Oda T, Shingu T, Takabayashi A, Adachi T, Semenza GL, and Fukuda K. The intravenous anesthetic propofol inhibits hypoxia-inducible factor 1 activity in an oxygen tension-dependent manner. FEBS Lett 577: 434438, 2004.[CrossRef][Web of Science][Medline]
52. Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, and Tada K. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res 42: 15301536, 1982.
53. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, and Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26: 171176, 1980.[Web of Science][Medline]
54. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, and Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24: 65396549, 2004.
55. Wang GL, Jiang BH, Rue EA, and Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 55105514, 1995.
56. Waskiewicz A, Flynn A, Proud C, and Cooper J. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16: 19091920, 1997.[CrossRef][Web of Science][Medline]
57. Wood SM, Gleadle JM, Pugh CW, Hankinson O, and Ratcliffe PJ. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem 271: 1511715123, 1996.
58. Zimber A, Chedeville A, Abita JP, Barbu V, and Gespach C. Functional interactions between bile acids, all-trans retinoic acid, and 1,25-dihydroxy-vitamin D3 on monocytic differentiation and Myeloblastin gene down-regulation in HL60 and THP-1 human leukemia cells. Cancer Res 60: 672678, 2000.
This article has been cited by other articles:
![]() |
H.-Y. Fang, R. Hughes, C. Murdoch, S. B. Coffelt, S. K. Biswas, A. L. Harris, R. S. Johnson, H. Z. Imityaz, M. C. Simon, E. Fredlund, et al. Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia Blood, July 23, 2009; 114(4): 844 - 859. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Lysiak, J. L. Kirby, J. J. Tremblay, R. I. Woodson, M. A. Reardon, L. A. Palmer, and T. T. Turner Hypoxia-Inducible Factor-1{alpha} Is Constitutively Expressed in Murine Leydig Cells and Regulates 3{beta}-Hydroxysteroid Dehydrogenase Type 1 Promoter Activity J Androl, March 1, 2009; 30(2): 146 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, L.-P. Song, Y. Huang, Q. Zhao, K.-W. Zhao, and G.-Q. Chen Accumulation of hypoxia-inducible factor-1{alpha} protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid Haematologica, October 1, 2008; 93(10): 1480 - 1487. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. De Ponti, R. Carini, E. Alchera, M. P. Nitti, M. Locati, E. Albano, G. Cairo, and L. Tacchini Adenosine A2a receptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages J. Leukoc. Biol., August 1, 2007; 82(2): 392 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Nemery and J. L. Abraham Hard Metal Lung Disease: Still Hard to Understand Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 2 - 3. [Full Text] [PDF] |
||||
![]() |
A. Degrossoli and S. Giorgio Functional Alterations in Macrophages After Hypoxia Selection Experimental Biology and Medicine, January 1, 2007; 232(1): 88 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. I. L. Hwang, I. R. Watson, S. D. Der, and M. Ohh Loss of VHL Confers Hypoxia-Inducible Factor (HIF)-Dependent Resistance to Vesicular Stomatitis Virus: Role of HIF in Antiviral Response J. Virol., November 1, 2006; 80(21): 10712 - 10723. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |